JPWO2021007245A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021007245A5 JPWO2021007245A5 JP2022500683A JP2022500683A JPWO2021007245A5 JP WO2021007245 A5 JPWO2021007245 A5 JP WO2021007245A5 JP 2022500683 A JP2022500683 A JP 2022500683A JP 2022500683 A JP2022500683 A JP 2022500683A JP WO2021007245 A5 JPWO2021007245 A5 JP WO2021007245A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- treatment
- patient
- bipolar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962871170P | 2019-07-07 | 2019-07-07 | |
| US62/871,170 | 2019-07-07 | ||
| PCT/US2020/041063 WO2021007245A1 (en) | 2019-07-07 | 2020-07-07 | Novel methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022539821A JP2022539821A (ja) | 2022-09-13 |
| JPWO2021007245A5 true JPWO2021007245A5 (ru) | 2023-07-14 |
Family
ID=74066254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022500683A Pending JP2022539821A (ja) | 2019-07-07 | 2020-07-07 | 新規方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20210000822A1 (ru) |
| EP (2) | EP3993798A4 (ru) |
| JP (1) | JP2022539821A (ru) |
| KR (1) | KR20220029744A (ru) |
| CN (1) | CN114072150A (ru) |
| AU (1) | AU2020311894A1 (ru) |
| BR (1) | BR112022000231A2 (ru) |
| CA (1) | CA3141223A1 (ru) |
| IL (1) | IL289589A (ru) |
| MX (1) | MX2022000143A (ru) |
| WO (1) | WO2021007245A1 (ru) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021338439A1 (en) * | 2020-09-04 | 2023-02-23 | Intra-Cellular Therapies, Inc. | Novel salts, crystals, and co-crystals |
| WO2024030835A2 (en) * | 2022-07-30 | 2024-02-08 | Intra-Cellular Therapies, Inc. | Novel salts and crystals |
| CN115671057A (zh) * | 2022-10-19 | 2023-02-03 | 四川迈可隆生物科技有限公司 | 一种卢美哌隆药物组合物、长效微球缓释制剂及其制备方法 |
| CN115554237B (zh) * | 2022-12-08 | 2023-09-12 | 山东则正医药技术有限公司 | 一种卢美哌隆原位凝胶长效注射剂及其制备方法和用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| DE60014083T2 (de) | 1999-06-15 | 2006-03-02 | Bristol-Myers Squibb Pharma Co., Wilmington | Substituierte heterocyclylkondensierte gamma carboline |
| US6713471B1 (en) | 1999-06-15 | 2004-03-30 | Bristol-Myers Squibb Pharma Company | Substituted heterocycle fused gamma-carbolines |
| MX2010010024A (es) | 2008-03-12 | 2010-11-09 | Intra Cellular Therapies Inc | Solido de gamma-carbolinas fusionadas con heterociclos substituidos. |
| CN105168219B (zh) | 2008-05-27 | 2018-11-20 | 细胞内治疗公司 | 用于睡眠障碍和其他疾病的方法和组合物 |
| JP5894574B2 (ja) | 2010-04-22 | 2016-03-30 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| RU2014145682A (ru) | 2012-04-14 | 2016-06-10 | Интра-Селлулар Терапиз, Инк | Органические соединения |
| WO2015085004A1 (en) * | 2013-12-03 | 2015-06-11 | Intra-Cellular Therapies, Inc. | Novel methods |
| KR20220054908A (ko) | 2014-04-04 | 2022-05-03 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| EP3125892A4 (en) * | 2014-04-04 | 2017-12-27 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2017117514A1 (en) * | 2015-12-31 | 2017-07-06 | Tung Roger D | Deuterated iti-007 |
| CN113754661A (zh) | 2016-03-25 | 2021-12-07 | 细胞内治疗公司 | 有机化合物 |
| WO2018031535A1 (en) * | 2016-08-09 | 2018-02-15 | Assia Chemical Industries Ltd. | Solid state forms of lumateperone ditosylate salt |
| CN112384218B (zh) | 2018-06-06 | 2024-04-26 | 细胞内治疗公司 | 盐和晶体 |
-
2020
- 2020-07-07 EP EP20837066.8A patent/EP3993798A4/en active Pending
- 2020-07-07 EP EP22191949.1A patent/EP4134101A1/en active Pending
- 2020-07-07 WO PCT/US2020/041063 patent/WO2021007245A1/en unknown
- 2020-07-07 CN CN202080049820.3A patent/CN114072150A/zh active Pending
- 2020-07-07 KR KR1020227003969A patent/KR20220029744A/ko unknown
- 2020-07-07 MX MX2022000143A patent/MX2022000143A/es unknown
- 2020-07-07 AU AU2020311894A patent/AU2020311894A1/en active Pending
- 2020-07-07 CA CA3141223A patent/CA3141223A1/en active Pending
- 2020-07-07 US US16/922,893 patent/US20210000822A1/en active Pending
- 2020-07-07 BR BR112022000231A patent/BR112022000231A2/pt unknown
- 2020-07-07 JP JP2022500683A patent/JP2022539821A/ja active Pending
-
2022
- 2022-01-03 IL IL289589A patent/IL289589A/en unknown
-
2023
- 2023-10-25 US US18/494,754 patent/US20240066030A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2275108B1 (en) | Pharmaceutical preparation comprising dpp-iv inhibitor and other diabetes therapeutic agent in concomitant or combined form | |
| ES2521672T3 (es) | Formulaciones farmacéuticas para el tratamiento del cáncer | |
| KR101718639B1 (ko) | 선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생 | |
| JP7069253B2 (ja) | 統合失調症を治療するための２－（（１－（２（４－フルオロフェニル）－２－オキソエチル）ピペリジン－４－イル）メチル）イソインドリン－１－オン | |
| BR112020014160A2 (pt) | Compostos de benzamida | |
| CN106304835A (zh) | sGC刺激剂 | |
| JP2009522371A (ja) | ウイルス性肝炎の処置 | |
| JP2015536973A (ja) | ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ−γキナーゼ阻害剤とを含有する薬学的組成物 | |
| JP2007518755A (ja) | モノアミン神経伝達物質再取り込み阻害剤及びｎ−メチル−ｄ−アスパラギン酸（ｎｍｄａ）受容体アンタゴニストを含む医薬組成物 | |
| JP6806685B2 (ja) | 急性放射線症候群を治療するための組成物及び方法 | |
| RU2493851C2 (ru) | Комбинация частичного агониста никотиновых рецепторов и ингибитора ацетилхолинестеразы, содержащая ее фармацевтическая композиция и ее применение в лечении когнитивных расстройств | |
| JP2021534115A (ja) | Ｂ細胞悪性腫瘍の処置 | |
| JPWO2021007245A5 (ru) | ||
| KR20130103650A (ko) | (ｅ)-4-카복시스티릴-4-클로로벤질설폰의 개선된 안정한 수성 제형 | |
| US20230060792A1 (en) | Targeting Mcl-1 to Enhance DNA Replication Stress Sensitivity for Cancer Therapy | |
| US20230277523A1 (en) | Methods for inhibiting phosphate transport | |
| EP3380104A1 (en) | An a3 adenosine receptor ligand for use in treating ectopic fat accumulation | |
| EP3763362B1 (en) | Method of treating idiopathic pulmonary fibrosis | |
| JP2018502863A (ja) | 白血病の治療のための４−（４−フルオロ−２−メトキシフェニル）−ｎ−｛３−［（ｓ−メチルスルホンイミドイル）メチル］フェニル｝−１，３，５−トリアジン−２−アミンの使用 | |
| KR20010105418A (ko) | 기분 장애 치료용 오사네턴트 | |
| CN111195250A (zh) | 西达本胺联合dice的应用及联合药物 | |
| RU2022102696A (ru) | Новые способы | |
| JPWO2020146440A5 (ru) | ||
| BR112020016389A2 (pt) | Uso de 5-fluor-4-(4-fluor-2-metoxifenil)-n-{4-[(s-metilsulfonimidoil)metil]piridin-2-il}piridin-2-amina para tratamento de linfoma difuso de células b grandes | |
| TW200911247A (en) | Use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for preparing a medicament for use in the treatment of motor disorders related to parkinson's disease |